Using β-Elemene to Reduce Stemness and Drug Resistance in Osteosarcoma: A Focus on the AKT/FOXO1 Signaling Pathway and Immune Modulation

Overview

Journal J Bone Oncol

Publisher Elsevier

Date 2025 Jan 24

PMID 39850453

Authors

Shaochun Zhang

Zhijie Xing

Jing Ke

Affiliations

Soon will be listed here.

Abstract

Objective: Osteosarcoma, a highly malignant bone tumor, poses significant treatment challenges due to its propensity for stemness and drug resistance, particularly against doxorubicin (DOX). This study aims to investigate the mechanism by which β-elemene reduces the stemness of osteosarcoma stem cells and ultimately decreases DOX resistance by inhibiting the Akt/FoxO1 signaling pathway and activating a macrophage-mediated inflammatory microenvironment.

Methods: Osteosarcoma stem cells were isolated and induced for DOX resistance. and models were employed to assess β-elemene's impact on cell viability, stemness, and drug resistance. Bioinformatics analysis, flow cytometry, and immunofluorescence staining were used to evaluate signaling pathway activity and macrophage polarization. Additionally, an osteosarcoma xenograft mouse model was established to confirm the therapeutic effects of β-elemene.

Results: animal experiments demonstrated that β-elemene reduces osteosarcoma resistance. Bioinformatics analysis revealed that AKT1 is a key core gene in osteosarcoma progression, acting through the FOXO signaling pathway. Additionally, AKT inhibits immune cell infiltration in osteosarcoma and suppresses immune responses during osteosarcoma progression. β-elemene may influence osteosarcoma progression by mediating TP53 to regulate PTEN and subsequently AKT1. experiments showed that β-elemene promotes M1 macrophage activation by inhibiting the Akt/FoxO1 signaling axis, thereby reducing the stemness of osteosarcoma stem cells. Finally, animal experiments confirmed that β-elemene reduces osteosarcoma resistance by promoting M1 macrophage activation through inhibition of the Akt/FoxO1 signaling axis.

Conclusion: β-Elemene demonstrates promising potential in reducing osteosarcoma stemness and drug resistance via dual mechanisms: targeting the AKT/FOXO1 pathway and modulating the tumor immune microenvironment. These findings suggest β-elemene as a potential adjunct therapy for osteosarcoma, providing novel therapeutic strategies to overcome chemotherapy resistance and improve patient outcomes.

References

Tsang S, Rainusso N, Liu M, Nomura M, Patel T, Nakahata K . LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination. Oncogene. 2022; 41(50):5373-5384. DOI: 10.1038/s41388-022-02538-w. View

Hu G, Wang D . Analysis of Cardiac Adverse Reactions Caused by Different Doses of Adriamycin Chemotherapy in Patients with Breast Cancer. J Healthc Eng. 2022; 2022:1642244. PMC: 8863445. DOI: 10.1155/2022/1642244. View

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

Majumder S, Ren L, Pushpakumar S, Sen U . Hydrogen sulphide mitigates homocysteine-induced apoptosis and matrix remodelling in mesangial cells through Akt/FOXO1 signalling cascade. Cell Signal. 2019; 61:66-77. PMC: 6561819. DOI: 10.1016/j.cellsig.2019.05.003. View

Gill J, Gorlick R . Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021; 18(10):609-624. DOI: 10.1038/s41571-021-00519-8. View

Regan D, Chow L, Das S, Haines L, Palmer E, Kurihara J . Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Clin Cancer Res. 2021; 28(4):662-676. PMC: 8866227. DOI: 10.1158/1078-0432.CCR-21-2105. View

Wei Z, Xia K, Zheng D, Gong C, Guo W . RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway. Mol Med. 2023; 29(1):133. PMC: 10548720. DOI: 10.1186/s10020-023-00722-6. View

Jiang C, Zhang N, Hu X, Wang H . Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer. 2021; 20(1):117. PMC: 8436438. DOI: 10.1186/s12943-021-01411-w. View

Panez-Toro I, Munoz-Garcia J, Vargas-Franco J, Renodon-Corniere A, Heymann M, Lezot F . Advances in Osteosarcoma. Curr Osteoporos Rep. 2023; 21(4):330-343. PMC: 10393907. DOI: 10.1007/s11914-023-00803-9. View

10.

Xu K, Yin N, Peng M, Stamatiades E, Shyu A, Li P . Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science. 2021; 371(6527):405-410. PMC: 8380312. DOI: 10.1126/science.abb2683. View

11.

Chen C, Wang S, Wang J, Yao F, Tang X, Guo W . Nanosized drug delivery strategies in osteosarcoma chemotherapy. APL Bioeng. 2023; 7(1):011501. PMC: 9957606. DOI: 10.1063/5.0137026. View

12.

Ho D, Agaram N, Jean M, Suser S, Chu C, Vanderbilt C . Deep Learning-Based Objective and Reproducible Osteosarcoma Chemotherapy Response Assessment and Outcome Prediction. Am J Pathol. 2022; 193(3):341-349. PMC: 10013034. DOI: 10.1016/j.ajpath.2022.12.004. View

13.

Zhang L, Zhao J, Hu X, Wang C, Jia Y, Zhu C . A Peritumorally Injected Immunomodulating Adjuvant Elicits Robust and Safe Metalloimmunotherapy against Solid Tumors. Adv Mater. 2022; 34(41):e2206915. DOI: 10.1002/adma.202206915. View

14.

Hay N . Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. 2011; 1813(11):1965-70. PMC: 3427795. DOI: 10.1016/j.bbamcr.2011.03.013. View

15.

Chen Y, Yan H, Yan L, Wang X, Che X, Hou K . Hypoxia-induced ALDH3A1 promotes the proliferation of non-small-cell lung cancer by regulating energy metabolism reprogramming. Cell Death Dis. 2023; 14(9):617. PMC: 10511739. DOI: 10.1038/s41419-023-06142-y. View

16.

Fang Q, Que T, Liu B, Dan W, Wei Y, Ren B . β-ionone Inhibits Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Cells by Negatively Regulating the Wnt/β-Catenin Pathway. Front Biosci (Landmark Ed). 2023; 27(12):335. DOI: 10.31083/j.fbl2712335. View

17.

Hu Y, Han L, Xu W, Li T, Zhao Q, Lu W . CARD11 regulates the thymic Treg development in an NF-κB-independent manner. Front Immunol. 2024; 15:1364957. PMC: 11033321. DOI: 10.3389/fimmu.2024.1364957. View

18.

Burgering B, Kops G . Cell cycle and death control: long live Forkheads. Trends Biochem Sci. 2002; 27(7):352-60. DOI: 10.1016/s0968-0004(02)02113-8. View

19.

Orabi M, Orabi E, Abdullah Al Awadh A, Alshahrani M, Abdel-Wahab B, Sakagami H . New Megastigmane and Polyphenolic Components of Henna Leaves and Their Tumor-Specific Cytotoxicity on Human Oral Squamous Carcinoma Cell Lines. Antioxidants (Basel). 2023; 12(11). PMC: 10669829. DOI: 10.3390/antiox12111951. View

20.

Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C . Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization. J Immunol. 2017; 198(3):1006-1014. DOI: 10.4049/jimmunol.1601515. View